Actinogen Medical Limited (ATGGF)
| Previous close | 0.0000 |
| Open | 0.0150 |
| Bid | 0.0016 x 0 |
| Ask | 1.0000 x 0 |
| Day's range | 0.0150 - 0.0150 |
| 52-week range | 0.0150 - 0.0150 |
| Volume | |
| Avg. volume | 507 |
| Market cap | 55.385M |
| Beta (5Y monthly) | 1.74 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0000 |
| Earnings date | 29 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Actinogen Medical (ASX:ACW) shareholder returns have been enviable, earning 506% in 5 years
Actinogen Medical Limited ( ASX:ACW ) shareholders might be rather concerned because the share price has dropped 47% in...
PR NewswireActinogen announces further positive results on depression in the XanCIDD phase 2a trial
Actinogen Medical ASX: ACW ("ACW" or "the Company") announces that on-going analysis of the XanaCIDD phase 2a depression trial data found a consistent benefit of Xanamem® treatment on symptoms of depression in a variety of different endpoints. The consistent benefits observed support the conclusion that a 10 mg Xanamem dose is active in controlling brain cortisol and has clinically significant anti-depressant activity.
- PR Newswire
Actinogen announces achievement of clinically and statistically significant superiority of Xanamem® over placebo on depression in XanaCIDD phase 2a trial
Actinogen Medical ASX: ACW ("ACW" or "the Company") announces that Xanamem treatment had clinically and statistically significant (p < 0.05) benefits on depression in its phase 2a XanaCIDD trial of Xanamem in patients with cognitive dysfunction and major depressive disorder (MDD). This outcome indicates potential modification of the underlying biology of depression as a result of inhibition of tissue cortisol synthesis – a completely novel mechanism for the treatment of depression. The trial did
